A stepped wedge trial of efficacy and scalability of a virtual clinical pharmacy service (VCPS) in rural and remote NSW health facilities.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
04 May 2020
Historique:
received: 30 03 2020
accepted: 15 04 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 21 11 2020
Statut: epublish

Résumé

Medication errors are a leading cause of mortality and morbidity. Clinical pharmacy services provided in hospital can reduce medication errors and medication related harm. However, few rural or remote hospitals in Australia have a clinical pharmacy service. This study will evaluate a virtual clinical pharmacy service (VCPS) provided via telehealth to eight rural and remote hospitals in NSW, Australia. A stepped wedge cluster randomised trial design will use routinely collected data from patients' electronic medical records (n = 2080) to evaluate the VCPS at eight facilities. The sequence of steps is randomised, allowing for control of potential confounding temporal trends. Primary outcomes are number of medication reconciliations completed on admission and discharge. Secondary outcomes are length of stay, falls and 28 day readmissions. A cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) will be conducted. The CEA will answer the question of whether the VCPS is more cost-effective compared to treatment as usual; the CBA will consider the rate of return on investing in the VCPS. A patient experience measure (n = 500) and medication adherence questionnaire (n = 100 pre and post) will also be used to identify patient responses to the virtual service. Focus groups will investigate implementation from hospital staff perspectives at each site. Analyses of routine data will comprise generalised linear mixed models. Descriptive statistical analysis will summarise patient experience responses. Differences in medication adherence will be compared using linear regression models. Thematic analysis of focus groups will identify barriers and facilitators to VCPS implementation. We aim to demonstrate the effectiveness of virtual pharmacy interventions for rural populations, and inform best practice for using virtual healthcare to improve access to pharmacy services. It is widely recognised that clinical pharmacists are best placed to reduce medication errors. However, pharmacy services are limited in rural and remote hospitals. This project will provide evidence about ways in which the benefits of hospital pharmacists can be maximised utilising telehealth technology. If successful, this project can provide a model for pharmacy delivery in rural and remote locations. Australian New Zealand Clinical Trials Registry (ANZCTR) -ACTRN12619001757101 Prospectively registered on 11 December 2019. Record available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378878&isReview=true.

Sections du résumé

BACKGROUND BACKGROUND
Medication errors are a leading cause of mortality and morbidity. Clinical pharmacy services provided in hospital can reduce medication errors and medication related harm. However, few rural or remote hospitals in Australia have a clinical pharmacy service. This study will evaluate a virtual clinical pharmacy service (VCPS) provided via telehealth to eight rural and remote hospitals in NSW, Australia.
METHODS METHODS
A stepped wedge cluster randomised trial design will use routinely collected data from patients' electronic medical records (n = 2080) to evaluate the VCPS at eight facilities. The sequence of steps is randomised, allowing for control of potential confounding temporal trends. Primary outcomes are number of medication reconciliations completed on admission and discharge. Secondary outcomes are length of stay, falls and 28 day readmissions. A cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) will be conducted. The CEA will answer the question of whether the VCPS is more cost-effective compared to treatment as usual; the CBA will consider the rate of return on investing in the VCPS. A patient experience measure (n = 500) and medication adherence questionnaire (n = 100 pre and post) will also be used to identify patient responses to the virtual service. Focus groups will investigate implementation from hospital staff perspectives at each site. Analyses of routine data will comprise generalised linear mixed models. Descriptive statistical analysis will summarise patient experience responses. Differences in medication adherence will be compared using linear regression models. Thematic analysis of focus groups will identify barriers and facilitators to VCPS implementation.
DISCUSSION CONCLUSIONS
We aim to demonstrate the effectiveness of virtual pharmacy interventions for rural populations, and inform best practice for using virtual healthcare to improve access to pharmacy services. It is widely recognised that clinical pharmacists are best placed to reduce medication errors. However, pharmacy services are limited in rural and remote hospitals. This project will provide evidence about ways in which the benefits of hospital pharmacists can be maximised utilising telehealth technology. If successful, this project can provide a model for pharmacy delivery in rural and remote locations.
TRIAL REGISTRATION BACKGROUND
Australian New Zealand Clinical Trials Registry (ANZCTR) -ACTRN12619001757101 Prospectively registered on 11 December 2019. Record available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378878&isReview=true.

Identifiants

pubmed: 32366308
doi: 10.1186/s12913-020-05229-y
pii: 10.1186/s12913-020-05229-y
pmc: PMC7197111
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

373

Subventions

Organisme : NSW Ministry of Health
ID : FE7801

Références

BMC Public Health. 2011 Dec 15;11:934
pubmed: 22168312
BMJ Open. 2016 Feb 23;6(2):e010003
pubmed: 26908524
Aust J Rural Health. 2012 Jun;20(3):138-43
pubmed: 22620478
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Integr Pharm Res Pract. 2016 Oct 26;5:75-82
pubmed: 29354542
Health Res Policy Syst. 2016 Aug 09;14(1):60
pubmed: 27507300
J Telemed Telecare. 2010;16(2):95-9
pubmed: 20139138
J Telemed Telecare. 2017 Dec;23(10):861-865
pubmed: 29081271
Aust N Z J Public Health. 2017 Feb;41(1):48-53
pubmed: 27868300
Res Nurs Health. 2009 Feb;32(1):110-21
pubmed: 19035619
Res Social Adm Pharm. 2012 Sep-Oct;8(5):420-32
pubmed: 22222342
JAMA Intern Med. 2018 Mar 1;178(3):375-382
pubmed: 29379953
Dig Dis Sci. 2019 Oct;64(10):2784-2797
pubmed: 31037593
Int J Evid Based Healthc. 2016 Sep;14(3):113-22
pubmed: 26886682
Med J Aust. 2017 Jan 16;206(1):36-39
pubmed: 28076735
Lancet. 2017 Apr 29;389(10080):1680-1681
pubmed: 28463129

Auteurs

Julaine Allan (J)

School of Health and Society, University of Wollongong, Wollongong, Australia. julaineallan@gmail.com.

Shannon Nott (S)

Western NSW Local Health District, Dubbo, Australia.

Brett Chambers (B)

Western NSW Local Health District, Dubbo, Australia.

Ged Hawthorn (G)

Western NSW Local Health District, Dubbo, Australia.

Alice Munro (A)

Western NSW Local Health District, Dubbo, Australia.

Chris Doran (C)

Central Queensland University, Brisbane, Australia.

Chris Oldmeadow (C)

Hunter Medical Research Institute, Newcastle, Australia.

Clare Coleman (C)

Western NSW Local Health District, Dubbo, Australia.

Teesta Saksena (T)

Western NSW Local Health District, Dubbo, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH